Delving into the Latest Updates on Tianjin Gudui Biomedical Technology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Immune System Diseases

Hemic and Lymphatic Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	7
Immune System Diseases	4
Nervous System Diseases	3
Hemic and Lymphatic Diseases	2
Infectious Diseases	2
Endocrinology and Metabolic Disease	2

Top 5 Drug Type	Count

Small molecule drug	8
Chemical drugs	1

Top 5 Target	Count

MSMP(microseminoprotein, prostate associated)	1

主要目的：评价健康研究参与者单次和多次口服GD-20片的安全性和耐受性；次要目的：评价健康研究参与者单次和多次口服GD-20片的药代动力学特征。探索性目的：探索健康研究参与者单次口服GD-20片的人体排泄率数据和主要排泄途径。

[Translation]

Primary objective: To evaluate the safety and tolerability of single and multiple oral administration of GD-20 tablets in healthy research participants; Secondary objective: To evaluate the pharmacokinetic characteristics of single and multiple oral administration of GD-20 tablets in healthy research participants. Exploratory objective: To explore the human excretion rate data and main excretion pathways of single oral administration of GD-20 tablets in healthy research participants.

Start Date06 Mar 2025

Sponsor / Collaborator

Tianjin Gudui Biomedical Technology Co., Ltd.

CTR20253809

/ Not yet recruitingPhase 1

在健康受试者中的安全性、耐受性及PK特征的随机、双盲、安慰剂和阳性药对照、单次和多次给药剂量递增的I期临床试验

[Translation] A randomized, double-blind, placebo- and active drug-controlled, single- and multiple-dose ascending phase I clinical trial to investigate the safety, tolerability, and PK characteristics of the drug in healthy subjects.

主要目的：评估在健康受试者中单次和/或多次静脉给予GD-19乳状注射液的安全性和耐受性。次要目的：评价GD-19乳状注射液在健康受试者中的药代动力学特征（PK）和物质平衡。

[Translation]

Primary objective: To evaluate the safety and tolerability of single and/or multiple intravenous administrations of GD-19 emulsion injection in healthy subjects. Secondary objective: To evaluate the pharmacokinetic characteristics (PK) and material balance of GD-19 emulsion injection in healthy subjects.

Start Date-

Sponsor / Collaborator

Tianjin Gudui Biomedical Technology Co., Ltd.

[+1]

100 Clinical Results associated with Tianjin Gudui Biomedical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Tianjin Gudui Biomedical Technology Co., Ltd.

Login to view more data

100 Deals associated with Tianjin Gudui Biomedical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Tianjin Gudui Biomedical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Jun 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

5

Preclinical

Phase 1

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

GD-19(Tianjin Gudui )	Cancer Pain More	Phase 1
GD-20	Neuromyelitis Optica More	IND Approval
GD-07	Colorectal Cancer More	Preclinical
GD-13	Colorectal Cancer More	Preclinical
GD-12	Hodgkin's Lymphoma More	Preclinical